{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:22:41Z","timestamp":1762082561906,"version":"build-2065373602"},"reference-count":54,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018712","name":"University of Medicine and Pharmacy, Cluj-Napoca, Romania","doi-asserted-by":"publisher","award":["PCD 2018-No. 7690\/94\/19.01.2018"],"award-info":[{"award-number":["PCD 2018-No. 7690\/94\/19.01.2018"]}],"id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Dual antiplatelet therapy (DAPT) is essential in the treatment of patients with acute coronary syndrome (ACS). The objective of this study was to evaluate the effectiveness of antiplatelet medication in our practice and to investigate the factors that influence it. Materials and Methods: A prospective cohort observational study was conducted, in which 193 patients with ACS were enrolled. The patients were stented in the catheterization laboratory between May 2019 and October 2020, before and during the COVID-19 pandemic, and were receiving DAPT. Their platelet functions were tested using a Multiplate Analyzer. In addition to this, clinical data, demographics, laboratory tests, and cardiovascular risk factors were also analyzed. Results: 43.46% of the patients treated with aspirin were found to be resistant to it. This phenomenon was more common in men (48.17% vs. 31.48%, p = 0.036), and it was associated with being under the age of 50 (OR: 2.08; 95% CI: 1.11\u20133.90) and weighing over 70 kg (OR: 3.00; 95% CI: 1.21\u20137.40). Most of the patients treated with clopidogrel were in the optimal treatment window, while about half of the patients treated with ticagrelor had an exaggerated pharmacological response. Among the laboratory parameters, leukocytosis and platelet count were found to be determinants of platelet reactivity for both the aspirin and ticagrelor treatments. Conclusions: Many patients treated with antiplatelet agents are outside of the treatment window. The results obtained showed that low doses of gastro-resistant aspirin tablets are ineffective, and their efficacy can be influenced by various clinical and laboratory factors. Patients receiving ticagrelor have significantly reduced platelet reactivity, influenced only by certain laboratory indicators. The pandemic significantly influenced the results of the platelet aggregation tests only in patients treated with clopidogrel.<\/jats:p>","DOI":"10.3390\/medicina59010084","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T04:51:22Z","timestamp":1672635082000},"page":"84","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic"],"prefix":"10.3390","volume":"59","author":[{"given":"Ovidiu-Ionut","family":"Anchidin","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"},{"name":"\u201cNiculae Stancioiu\u201d Heart Institute, 400001 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan Horia","family":"Rosianu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"},{"name":"\u201cNiculae Stancioiu\u201d Heart Institute, 400001 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1311-435X","authenticated-orcid":false,"given":"Ancuta","family":"Nemes","sequence":"additional","affiliation":[{"name":"\u201cNiculae Stancioiu\u201d Heart Institute, 400001 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Aldica","sequence":"additional","affiliation":[{"name":"\u201cNiculae Stancioiu\u201d Heart Institute, 400001 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-8582","authenticated-orcid":false,"given":"Dan","family":"Blendea","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"},{"name":"\u201cNiculae Stancioiu\u201d Heart Institute, 400001 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Molnar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"},{"name":"\u201cNiculae Stancioiu\u201d Heart Institute, 400001 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2241-279X","authenticated-orcid":false,"given":"Horatiu","family":"Moldovan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Bucharest Clinical Emergency Hospital, 014461 Bucharest, Romania"},{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Pop","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"},{"name":"Department of Cardiology, Clinical Rehabilitation Hospital, 400437 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, November 13). Available online: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases#tab=tab_1."},{"key":"ref_2","first-page":"167","article-title":"Coronary artery disease: Pathogenesis and acute coronary syndromes","volume":"68","author":"Worthley","year":"2001","journal-title":"Mt. Sinai J. Med. N. Y."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mu\u0107ka, S., Miodo\u0144ska, M., Jakubiak, G.K., Starzak, M., Cie\u015blar, G., and Stanek, A. (2022). Endothelial Function Assessment by Flow-Mediated Dilation Method: A Valuable Tool in the Evaluation of the Cardiovascular System. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph191811242"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Jakubiak, G.K., Pawlas, N., Cie\u015blar, G., and Stanek, A. (2021). Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph182211970"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/eurheartj\/ehr479","article-title":"Lower risk of stent thrombosis and restenosis with unrestricted use of \u2018new-generation\u2019 drug-eluting stents: A report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"33","author":"Sarno","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"J. Am. Coll. Cardiol. Intv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e13102","DOI":"10.1111\/eci.13102","article-title":"Platelet reactivity patterns in patients treated with dual antiplatelet therapy","volume":"49","author":"Winter","year":"2019","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1007\/s12325-021-01803-w","article-title":"Platelet Reactivity and Coagulation Markers in Patients with COVID-19","volume":"38","author":"Bertolin","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gremmel, T., Bhatt, D.L., and Michelson, A.D. (2019). Laboratory monitoring of antiplatelet therapy. Platelets, Academic Press. [4th ed.].","DOI":"10.1016\/B978-0-12-813456-6.00036-9"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1160\/TH15-11-0870","article-title":"Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response a review of the literature","volume":"116","author":"Bordet","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1001\/jama.2021.19608","article-title":"Myocardial Infarction During the COVID-19 Pandemic","volume":"326","author":"Fanaroff","year":"2021","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"844701","DOI":"10.3389\/fimmu.2022.844701","article-title":"Disease Severity in Moderate-to-Severe COVID-19 Is Associated with Platelet Hyperreactivity and Innate Immune Activation","volume":"13","author":"Jakobs","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/ALN.0000000000003685","article-title":"Greater Fibrinolysis Resistance but No Greater Platelet Aggregation in Critically Ill COVID-19 Patients","volume":"134","author":"Heinz","year":"2021","journal-title":"Anesthesiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/eurheartj\/ehv137","article-title":"More transparency for a therapeutic window in platelet P2Y12 inhibition?","volume":"36","author":"Storey","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1309\/AJCPP43SEYCBJLHJ","article-title":"Reference range determination for whole-blood platelet aggregation using the multiplate analyzer","volume":"142","author":"Peerschke","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2014.06.1157","article-title":"Aspirin Treatment and Outcomes in Patients Undergoing Percutaneous Coronary Intervention: Is There a Role for Pharmacodynamic Testing?","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC Guideline for the Management of Patients With Non\u2013ST-Elevation Acute Coronary Syndromes: Executive Summary","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease","volume":"384","author":"Jones","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_29","unstructured":"(2022, March 22). Anm.ro. Available online: https:\/\/www.anm.ro\/_\/_PRO\/PRO_8517_14.01.16.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","article-title":"Drug resistance and pseudoresistance: An unintended consequence of enteric coating aspirin","volume":"127","author":"Grosser","year":"2013","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fcvm.2019.00109","article-title":"Platelet Function in Aging","volume":"6","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: Analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.diabet.2019.11.002","article-title":"Determinants of aspirin resistance in patients with type 2 diabetes","volume":"46","author":"Paven","year":"2020","journal-title":"Diabetes Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/03009734.2013.861549","article-title":"Aspirin resistance in patients with type II diabetes mellitus","volume":"119","author":"Tasdemir","year":"2014","journal-title":"Upsala J. Med. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0735-1097(02)02484-1","article-title":"Relationship between Baseline White Blood Cell Count and Degree of Coronary Artery Disease and Mortality in Patients with Acute Coronary Syndromes A TACTICS-TIMI 18 Substudy","volume":"40","author":"Sabatine","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.amjcard.2019.12.007","article-title":"Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients with Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial)","volume":"125","author":"Alkhalfan","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41569-021-00665-7","article-title":"Current and novel biomarkers of thrombotic risk in COVID-19: A Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium","volume":"19","author":"Gorog","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood.2020007214","article-title":"Platelet gene expression and function in patients with COVID-19","volume":"136","author":"Manne","year":"2020","journal-title":"Blood"},{"key":"ref_39","unstructured":"Recovery Collaborative Group (2022). Aspirin in patients admitted to hospital with COVID-19 (Recovery): A randomised, controlled, open-label, platform trial. Lancet, 399, 143\u2013151."},{"key":"ref_40","first-page":"85","article-title":"Mean platelet volume and platelet count: Overlooked markers of high on-treatment platelet reactivity and worse outcome in patients with acute coronary syndrome","volume":"14","author":"Jakl","year":"2014","journal-title":"Anadolu Kardiyol. Derg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcard.2009.01.037","article-title":"Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin","volume":"143","author":"Diodati","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.jcin.2017.08.044","article-title":"Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study","volume":"10","author":"Deharo","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, Predictors, and Impact of Post-Discharge Bleeding after Percutaneous Coronary Intervention","volume":"66","author":"Giustino","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/eurheartj\/ehx253","article-title":"Clopidogrel instead of prasugrel or ticagrelor after 1 month in stabilized ACS patients: Back to square one for DAPT?","volume":"38","author":"Sinnaeve","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: A network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.964395","article-title":"Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: A substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"5","author":"Husted","year":"2012","journal-title":"Circ Cardiovasc. Qual. Outcomes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.2015.1056151","article-title":"Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor","volume":"16","author":"Verdoia","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/jci.insight.139437","article-title":"Intravascular hemolysis triggers ADP-mediated generation of platelet-rich thrombi in precapillary pulmonary arterioles","volume":"5","author":"Brzoska","year":"2020","journal-title":"JCI Insight"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non\u2013Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial","volume":"327","author":"Berger","year":"2022","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/09537104.2021.1934667","article-title":"Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: A PLATO substudy","volume":"33","author":"Nelson","year":"2022","journal-title":"Platelets"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/01.CIR.0000116764.53225.A9","article-title":"Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications from a Prospective Cohort Study","volume":"109","author":"McAlister","year":"2004","journal-title":"Circulation"},{"key":"ref_53","unstructured":"(2022, March 22). Ema.europa.eu. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brilique-epar-product-information_en.pdf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the platelet inhibition and patient outcomes (PLATO) trial","volume":"122","author":"James","year":"2010","journal-title":"Circulation"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/1\/84\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:56:30Z","timestamp":1760147790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/1\/84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["medicina59010084"],"URL":"https:\/\/doi.org\/10.3390\/medicina59010084","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}